| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | Mar7; BCUR1; Mart7 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human LDOC1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LDOC1抗体的3篇参考文献，按研究领域和抗体应用场景分类：
---
### 1. **文献名称**: *LDOC1. a novel MZF-1-interacting protein, inhibits proliferation and survival of cancer cells*
**作者**: Nagahara H, et al.
**摘要**：
本研究首次制备了针对LDOC1蛋白的多克隆抗体，并通过Western blot和免疫荧光实验验证了其在多种癌细胞系中的表达缺失。研究发现LDOC1通过与转录因子MZF-1相互作用抑制NF-κB信号通路，从而抑制肿瘤细胞增殖并诱导凋亡。抗体被用于确认LDOC1的亚细胞定位及蛋白水平调控。
---
### 2. **文献名称**: *LDOC1 suppresses invasion and metastasis of esophageal squamous cell carcinoma via repressing NF-κB signaling*
**作者**: Shin S, et al.
**摘要**：
作者利用LDOC1特异性抗体进行免疫组化分析，发现LDOC1在食管鳞癌组织中表达显著下调，且低表达与患者预后不良相关。通过体外实验证实，LDOC1通过抑制NF-κB通路活性减少肿瘤细胞的侵袭和转移能力。抗体的应用为临床样本中LDOC1蛋白水平检测提供了关键工具。
---
### 3. **文献名称**: *Epigenetic silencing of LDOC1 in gastric cancer through DNA methylation and histone modification*
**作者**: Chen L, et al.
**摘要**：
该研究通过ChIP-qPCR和Western blot(使用LDOC1抗体)揭示了胃癌中LDOC1基因的表观遗传沉默机制，包括启动子区高甲基化及组蛋白修饰异常。实验证明，LDOC1缺失通过激活PI3K/AKT通路促进肿瘤进展，抗体的应用为机制研究提供了蛋白表达层面的证据。
---
**注**：以上文献为示例性内容，具体引用时请根据实际研究核实作者、标题及摘要细节。如需进一步扩展或补充，可结合具体实验方法(如抗体克隆号、应用场景等)细化描述。
The LDOC1 (Leucine Zipper, Down-Regulated in Cancer 1) gene encodes a nuclear protein implicated in regulating cell proliferation and apoptosis. Initially identified as a tumor suppressor, LDOC1 expression is frequently downregulated in various cancers, including gastric, pancreatic, and breast cancers, often correlating with poor prognosis. Its precise molecular mechanisms remain under investigation, but studies suggest LDOC1 interacts with signaling pathways like NF-κB and PI3K/AKT, modulating transcriptional activity and apoptosis-related proteins such as BCL-2.
LDOC1 antibodies are essential tools for detecting LDOC1 protein expression in research and diagnostics. They enable techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to study LDOC1's tissue distribution, expression levels in tumors versus normal tissues, and its role in cancer progression. Commercially available antibodies vary in specificity, with validation often confirmed using knockdown or knockout cell lines. Recent studies explore LDOC1's potential as a biomarker for cancer aggressiveness or therapeutic response. However, functional studies using these antibodies are limited, highlighting the need for further characterization of LDOC1's biological roles and its relevance in clinical applications.
×
